EMAS Position Statements and Clincial Guides
EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosisOsteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.
EMAS position statement: Vitamin D and postmenopausal healthThere is emerging evidence on the widespread tissue effects of vitamin D.
EMAS position statement: Managing menopausal women with a personal or family history of VTEVenous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a serious cardiovascular event whose incidence rises with increasing age.